<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  A novel nanoformulation drug delivery platform to overcome poorly soluble drug challenges.</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>08/01/2021</AwardEffectiveDate>
<AwardExpirationDate>07/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>255961.00</AwardTotalIntnAmount>
<AwardAmount>255961</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Kaitlin Bratlie</SignBlockName>
<PO_EMAI>kbratlie@nsf.gov</PO_EMAI>
<PO_PHON>7032922638</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project accelerates drug development.  The proposed method of producing preclinical drug formulations will accelerate and improve the success rate of drug development for a variety of disease areas where existing methods have not yet proven to be effective. Currently, the average wait time for a researched drug to reach patients at scale is 10-12 years, with only a 0.0002% approval rating. The proposed technology uses nanoparticles without additional chemicals or solvents, a mechanism that is versatile and adaptable for many drug delivery forms.  In addition to accelerating drug development it enables new therapeutics currently administered in clinical settings. &lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase I project creates a platform to overcome poorly soluble drug formulation and delivery challenges. While great progress has been made in developing drug candidates, still the majority are insoluble in water (&gt;80%) and have low bioavailability, resulting in 40% failed preclinical studies due to improper formulations. This project develops and validates a nanoparticle compound generation platform that improves the bioavailability of poorly soluble drugs. The specific work will: (1) Identify the critical technology platform parameters for robust nanoparticle generation at scale; (2) Explore the delivery properties of various nanoparticle drug carriers; and (3) Improve the measurement accuracy of a nanodrug dissolution assay.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>07/23/2021</MinAmdLetterDate>
<MaxAmdLetterDate>07/23/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2126985</AwardID>
<Investigator>
<FirstName>Kay</FirstName>
<LastName>Olmstead</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Kay Olmstead</PI_FULL_NAME>
<EmailAddress>olmstead@kayolmstead.com</EmailAddress>
<PI_PHON>8582088419</PI_PHON>
<NSF_ID>000825337</NSF_ID>
<StartDate>07/23/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>NANO PHARMASOLUTIONS INC.</Name>
<CityName>ESCONDIDO</CityName>
<ZipCode>920274100</ZipCode>
<PhoneNumber>8582088419</PhoneNumber>
<StreetAddress>1435 LOGAN CT</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<StateCode>CA</StateCode>
<CONGRESSDISTRICT>50</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CA50</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>117443883</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>NANO PHARMASOLUTIONS INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[NANO PHARMASOLUTIONS INC.]]></Name>
<CityName>ESCONDIDO</CityName>
<StateCode>CA</StateCode>
<ZipCode>920274100</ZipCode>
<StreetAddress><![CDATA[1435 LOGAN CT]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>50</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CA50</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>008E</Code>
<Text>Gene and Drug Delivery</Text>
</ProgramReference>
<ProgramReference>
<Code>6883</Code>
<Text>CHEMISTRY OF LIFE PROCESSES</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~255961</FUND_OBLG>
</Award>
</rootTag>
